Journal article icon

Journal article : Review

Towards new TB vaccines

Abstract:
Mycobacterium tuberculosis remains the leading cause of death attributed to a single infectious organism. Bacillus Calmette-Guerin (BCG), the standard vaccine against M. tuberculosis, is thought to prevent only 5% of all vaccine-preventable deaths due to tuberculosis, thus an alternative vaccine is required. One of the principal barriers to vaccine development against M. tuberculosis is the complexity of the immune response to infection, with uncertainty as to what constitutes an immunological correlate of protection. In this paper, we seek to give an overview of the immunology of M. tuberculosis infection, and by doing so, investigate possible targets of vaccine development. This encompasses the innate, adaptive, mucosal and humoral immune systems. Though MVA85A did not improve protection compared with BCG alone in a large-scale clinical trial, the correlates of protection this has revealed, in addition to promising results from candidate such as VPM1002, M72/ASO1E and H56:IC31 point to a brighter future in the field of TB vaccine development.
Publication status:
Published
Peer review status:
Peer reviewed

Actions


Access Document


Files:
Publisher copy:
10.1007/s00281-020-00794-0

Authors


More by this author
Institution:
University of Oxford
Division:
MSD
Department:
NDM
Sub department:
Jenner Institute
Role:
Author
ORCID:
0000-0002-2126-5142


Publisher:
Springer
Journal:
Seminars in Immunopathology More from this journal
Volume:
42
Issue:
3
Pages:
315-331
Publication date:
2020-03-18
Acceptance date:
2020-02-27
DOI:
EISSN:
1863-2300
ISSN:
1863-2297
Pmid:
32189035


Language:
English
Keywords:
Subtype:
Review
Pubs id:
1096983
Local pid:
pubs:1096983
Deposit date:
2021-01-11

Terms of use



Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP